UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: December 17, 2004
Date of earliest event reported: December 17, 2004
PFIZER INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
1-3619
|
13-5315170
|
|
(State or other Jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
10017
(Zip Code) |
Registrant's telephone number, including area code:
(212) 573-2323
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Events |
On December 17, 2004, Pfizer Inc. issued a press release announcing new information regarding the cardiovascular safety of its COX-2 inhibitor, Celebrex, based on an analysis of two long-term cancer trials. A copy of the press release is included as Exhibit 99 to this report and is incorporated herein by reference.
| Item 9.01 Financial Statements and Exhibits |
| (c) Exhibits | ||
| Exhibit 99 | Press Release of Pfizer Inc. dated December 17, 2004. |
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
|
PFIZER INC.
|
||
|
By: /s/Margaret M. Foran
Margaret M. Foran |
||
|
Title: Vice President-Corporate
Governance and Secretary |
||
| Dated: December 17, 2004 |
EXHIBIT INDEX
|
Exhibit No. |
Description |
| 99 |
Press Release of Pfizer Inc. dated December 17, 2004. |